
Read more here: science.xyz/news/series-d
✓Building a brighter tomorrow enabled by neural engineering

Read more here: science.xyz/news/series-d

We’ve closed a $400 million Series D financing with participation from @khoslaventures , Ackman Oxman Institute, @TenetHealthcare , @885Cap , @ycombinator , @protocollabs , and others.

Our co-founder and Chief Scientific Officer, @mardinly and our Medical Director for Brain-Computer Interfaces, Dr. Murat Günel, joined MIT’s @mcgovernmit for a seminar on our biohybrid neural interface research. The conversation covered how we combine engineered neurons with light-emitting implants in order to control the release of neurotransmitters in the brain.

Frank Brodie, our Chief Medical Officer for Ophthalmology, summarizes the PRIMA presentations at @aao_ophth, including the 36- month results from the PRIMA clinical trial. eyetube.net/meeting-coverage…

“I had perfect vision up to the age of 40, then I was diagnosed with Stargardt. Within four years, I was legally blind.” With PRIMA, our first clinical trial patient with Stargardt reads a word again.

This morning, Science received the 2026 Prix Galien award for Best Startup, recognizing the innovations around the continuing development of our vision restoration BCI, PRIMA. Thank you to @GalienFdn for this recognition.

Neurotech is Humanity’s Next Frontier! I’ve been investing in neurotech since 2021 and working with teams building BCIs, NeuroAI, and connectomics. It now feels like AI did in ~2019. We are entering an extraordinary era: neurotech already restores functions, it can enhance our capabilities, and will evolve what it means to be human. PLC Neurotech is the fund backing the extraordinary founders and defining companies of this booming industry.

The SciFi 2 Headstage. Helping researchers record neural data more effectively from day one.

“More than 5 million people around the world have an advanced form of age-related macular degeneration (AMD) called geographic atrophy, in which cells in the retinas die off." technologyreview.com/2026/10…


PRIMA is one of @TIME's Best Inventions of 2026. As the first brain-computer interface approved for commercial use in Europe for the restoration of central vision, PRIMA has given clinical trial patients with geographic atrophy the ability to read letters, numbers, and words again.

Our first blind patient in a clinical trial with Stargardt disease received the PRIMA implant and at his first rehab session, he saw a letter, and during his second session, he read a word. Watch the video:

At @aao_ophth 2026, Joseph Martel, MD, presented strong long term (36-month) outcomes from the PRIMAvera clinical trial. aao.org/newsroom/news-releas…


German Design Awards 2027 named our Axon Terminal as Winner in Excellent Product Design – Medical, Rehabilitation and Health Care.

Frank Brodie, MD, our Chief Medical Officer for Ophthalmology, joined the retina panel at Eyecelerator at @aao_ophth 2026 to discuss our PRIMA retinal implant.